Effects of oral administration of tamoxifen, toremifene, dehydroepiandrosterone, and vorozole on uterine histomorphology in the rat

Proceedings of the Society for Experimental Biology and Medicine

Volumn 223, Issue 3, 2000, Pages 288-294

  Nephew, Kenneth P ^a,e   Osborne, Elizabeth ^a   Lubet, Ronald A ^b   Grubbs, Clinton J ^c   Khan, Sohaib A ^d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e Indiana University School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRASTERONE; TAMOXIFEN; TAMOXIFEN CITRATE; TOREMIFENE; VOROZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER INHIBITION; DOSE RESPONSE; DRUG EFFICACY; ENDOMETRIUM CANCER; FEMALE; MYOMETRIUM; NONHUMAN; OVARY CANCER; RAT; RISK ASSESSMENT; UTERUS WEIGHT;

EID: 0034076817     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1373.2000.22341.x     Document Type: Article

References (50)

1. Knapp GG, Nayfield S, Parkinson DR, Prasad VK, Prorok PC, Sausville EA, Sigman CC. Clinical development plans for cancer chemopreventive agents: Tamoxifen. J Cell Biochem 20(Suppl):252-267, 1994.
2. Hayes DF, Van Zyl JA, Hacking A, Goedhals L, Bezwada WR, Mailliard JA, Jones SE, Vogel CL, Berris RB, Shemano I, Schoenfelder J. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 13:2556-2566, 1995.
3. Stenbygaard LE, Herrstedt J, Thomsen J, Svendsen KR, Engelholm SA, Dombernowsky P. Toremifene and tamoxifen in advanced breast cancer: A double-blind, cross-over trial. Breast Cancer Res Treat 25:57-63, 1993.
4. Kelloff GJ, Crowell JA, Boone CA, Steele VA, Lubet RA, Greenwald P, Alberts DS, Covey JM, Doody LA, Knapp GG, Nayfield S, Parkinson DR, Prasad VK, Prorok PC, Sausville EA, Sigman CC. Clinical development plans for cancer chemopreventive agents. J Cell Biochem 20(Suppl):141-267, 1994.
5. Nayfield SG, Karp JE, Ford LG, Dorr A, Kramer BS. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 83:1450-1459, 1991.
6. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-I Study. J Natl Cancer Inst 90:1371-1388, 1998.
7. Branham WS, Zehr DR, Sheehan DM. Differential sensitivity of rat uterine growth and epithelium hypertrophy to estrogens and antiestrogens. Proc Soc Exp Biol Med 203:297-303, 1993.
8. Tomas E, Kauppila A, Blanco G, Apaja-Sarkkinen M, Laatikainen T. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol Oncol 59:261-266, 1995.
9. Medlock KL, Branham WS, Sheehan DM. Effects of toremifene on neonatal rat uterine growth and differentiation. Biol Reprod 56:1239-1244, 1997.
10. Jordan VC. Alternate antiestrogens and approaches to the prevention of breast cancer. J Cell Biochem 22(Suppl):51-57, 1995.
11. Vande Weile R, Lieberman S. The metabolism of dehydroisoandrosterone. In: Pincus G, Vollmer E, Eds. Biological Activity of Steroids in Relation to Cancer. New York: Academic Press, pp93-110, 1960.
12. Longcope C. Metabolism of dehydroepiandrosterone. Ann N Y Acad Sci 774:143-1482, 1995.
13. Svec F, Porter JR. The actions of exogenous dehydroepiandrosterone in experimental animals and humans. Proc Soc Exp Biol Med 218:174-191, 1998.
14. Schwartz AG. Inhibition of spontaneous breast cancer formation in female C3H (A vy/a) mice by long-term treatment with dehydroepiandrosterone. Cancer Res 39:1129-1132, 1979.
15. Inano H, Ishii-Ohba H, Suzuki K, Yamanouchi H, Onoda M, Wakabayashi K. Chemoprevention by dietary dehydroepiandrosterone against promotion/progression phase of radiation-induced mammary tumorigenesis in rats. J Steroid Biochem Mol Biol 11:193-202, 1995.
16. McCormick DL, Rao KVN, Johnson WD, Bowman-Gram TA, Steele VE, Lubet RA, Kelloff GJ. Exceptional chemopreventive activity of low-dose dehydroepiandrosterone in the rat mammary gland. Cancer Res 56:1724-1726, 1996.
17. Lubet RA, Gordon GB, Prough RA, Lei XD, You M, Wang Y, Grubbs CJ, Steele VE, Kelloff GJ, Thomas CF, Moon RD. Modulation of methylnitrosourea-induced breast cancer in Sprague-Dawley rats by dehydroepiandrosterone: Dose-dependent inhibition, effects of limited exposure, effects on peroxisomal enzymes, and lack of effects on levels of Ha-Ras mutations. Cancer Res 58:921-926, 1998.
18. Harper MJK. Estrogenic effects of dehydroepiandrosterone and its sulfate in rats. Endocrinology 84:229-235, 1969.
19. Hipkin LJ. The effect of corticotrophin on the rat uterine weight response to human chorionic gonadotrophin. Acta Endocrinol (Copenh) 67:463-469, 1971.
20. Hipkin LJ. Augmentation of the rat uterine weight response to human chorionic gonadotrophin by various steroids. Acta Endocrinol (Copenh) 75:141-147, 1974.
21. Sourla A, Flamand M, Belanger A, Labrie F. Effect of dehydroepiandrosterone on vaginal and uterine histomorphology in the rat. J Steroid Biochem Mol Biol 66:137-149, 1998.
22. Wouters W, DeCoster R, Krekels M, van Dun J, Beerens D, Haelterman C, Raeymakers A, Freyne E, van Gelder J, Janssen PAJ. R76713, a new nonsteroidal aromatase inhibitor. J Steroid Biochem 32:781-788, 1989.
23. Wouters W, van Ginckel R, Krekels M, Bowden C, DeCoster R. Pharmacology of vorozole. J Steroid Biochem Mol Biol 44:617-621, 1993.
24. Lubet RA, Steele VE, Casebolt TL, Eto I, Kelloff GJ, Grubbs CJ. Chemopreventive effects of the aromatase inhibitor vorozole (R83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats. Carcinogenesis 15:2775-2780, 1994.
25. DeCoster R, VanGinckel R, Callens M, Goeminne N, Janssens B. Antitumoral and endocrine effects of (+) vorozole in rats bearing dimethylbenzanthracene-induced mammary tumors. Cancer Res 52:1240-1244, 1992.
26. Lubet RA, Steele VE, DeCoster R, Bowden C, You M, Juliana MM, Eto I, Kelloff GJ, Grubbs CJ. Chemopreventive effects of the aromatase inhibitor vorozole (R83842) in the methylnitrosourea-induced mammary cancer model. Carcinogenesis 19:1345-1351, 1998.
27. Borms M, Vandebroek J, Rutten J, Tytgat J, DeCoster R, Langenaeken C, Bruynseels J. Vorozole-racemate (R76713): A specific nonsteroidal aromatase inhibitor pilot study in advanced post-menopausal breast cancer. Eur J Cancer 6(Suppl):S84, 1993.
28. Johnston SRD, Smith IE, Doody D, Jacobs S, Robertshaw H, Dowsett M. Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer. Cancer Res 54:5875-5881, 1994.
29. De Jong PC, Ven Jvd Nortier HWR, Maitimu-Smeele I, Donker TH, Thijssen JHH, Slee PHTJ, Blankenstein RA. Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole. Cancer Res 57:2109-2111, 1997.
30. Goss PE, Clark RM, Ambus U, Weizel HAE, Wadden NA, Crump M, Walde D, Tye LM, De Coster R, Bruynseels J. Phase II study of vorozole (R82842) a new aromatase inhibitor in postmenopausal women with advanced breast cancer in progression on tamoxifen. Clin Cancer Res 1:287-294, 1995.
31. Lubet RA, Steele VE, Kelloff GJ, Eto I, Grubbs CJ. Chemopreventive efficacy of 9 cis retinoic acid (9CRA) administered singly or concurrently with torefimene, or vorozole, in the MNU-induced rat mammary tumor model. (abstract) Proc Am Assoc Cancer Res 39:197, 1998.
32. Nephew KP, Polek TC, Khan SA. Tamoxifen-induced proto-oncogene expression persists in uterine endometrial epithelium. Endocrinology 137:219-224, 1996.
33. Harper MJK, Walpole AL. A new derivative of triphenylethylene: Effect on implantation and mode of action in rats. J Reprod Fertil 13:101-119, 1967.
34. Martin L, Middleton E. Prolonged oestrogenic and mitogenic activity of tamoxifen in the ovariectomized mouse. J Endocrinol 78:125-129, 1978.
35. Holinka CF, Bressler RS, Zehr DR, Gurpide E. Comparison of effects of estertrol and tamoxifen with those of estriol and estradiol on the immature rat uterus. Biol Reprod 22:913-926, 1980.
36. Bigsby RM, Young CM. Estrogenic effects of the antiprogestin onapristone (ZK98.299) in the rodent uterus. Am J Obstet Gynecol 171:188-194, 1994.
37. Kallio S, Kangas L, Blanco G, Johansson R, Karjalainen A, Perila M, Pippo I, Sundquist H, Sodervall M, Toivola R. A new triphenylethylene compound, Fc-1157a. I. Hormonal effects. Cancer Chemother Pharmacol 17:103-108, 1986.
38. Greaves P, Goonetilleke R, Nunn G, Topham J, Orton T. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 53:3919-3924, 1993.
39. Rumpel E, Michna H, Kuhnel W. PCNA-immunoreactivity in the uterus of rats after treatment with the antiestrogen tamoxifen. Anat Anz 177:133-138, 1995.
40. Carthew P, Edwards RE, Nolan BM, Martin EA, Smith LL. Tamoxifen-associated uterine pathology in rodents: Relevance to women. Carcinogenesis 17:1577-1582, 1996.
41. Sandow BA, West NB, Norman RL, Brenner RM. Hormonal control of apoptosis in hamster uterine luminal epithelium. Am J Anat 156:15-36, 1979.
42. Nawaz S, Lynch MP, Galand P, Gerschenson LE. Hormonal regulation of cell death in rabbit uterine epithelium. Am J Pathol 127:51-59, 1987.
43. Pollard J, Pacey J, Cheng SVY, Jordan EG. Estrogens and cell death in murine luminal epithelium. Cell Tissue Res 249:533-540, 1987.
44. Rotello RJ, Hocker MB, Gerschenson LE. Biochemical evidence for programmed cell death in rabbit uterine epithelium. Am J Pathol 134:491-495, 1989.
45. Poortman J, Vroegindewey-Jie D, Thijssen JH, Schwarz F. Relative binding affinity of androstane and C-19-nor-androstane-steroids for the estradiol-receptor in human myometrial and mammary cancer tissue. Mol Cell Endocrinol 1:27-34, 1977.
46. Van Doom LG, Poortman J, Thijssen JH, Schwarz F. Actions and interactions of 85-androstene-3β,17β-diol and 17β-estradiol in the immature rat uterus. Endocrinology 108:1587-1593, 1981.
47. Bruder JM, Sobek L, Oettel M. Dehydroepiandrosterone stimulates the estrogen response element. J Steroid Biochem Mol Biol 62:421-466, 1997.
48. Nephew KP, Sheeler CQ, Dudley MD, Gordon S, Nayfield SG, Khan SA. Studies of DHEA with the human estrogen receptor in yeast. Mol Cell Endocrinol 143:133-142, 1998.
49. Labrie F. Intracrinology. Mol Cell Endocrinol 78:C113-C118, 1991.
50. Parker CR, Mahesh VB. Dehydroepiandrosterone (DHA)-induced precocious ovulation: Correlative changes in blood steroids, gonadotropins, and cytosol estradiol receptors of anterior pituitary gland and hypothalamus. J Steroid Biochem Mol Biol 8:173-177, 1977.